140 related articles for article (PubMed ID: 11903102)
41. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
Pahwa R; Koller WC
Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
[No Abstract] [Full Text] [Related]
42. Systematic review of levodopa dose equivalency reporting in Parkinson's disease.
Tomlinson CL; Stowe R; Patel S; Rick C; Gray R; Clarke CE
Mov Disord; 2010 Nov; 25(15):2649-53. PubMed ID: 21069833
[TBL] [Abstract][Full Text] [Related]
43. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
Reichmann H; Emre M
Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
[TBL] [Abstract][Full Text] [Related]
44. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
45. Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson's disease patients.
Senek M; Nyholm D; Nielsen EI
Eur J Clin Pharmacol; 2018 Oct; 74(10):1299-1307. PubMed ID: 29882153
[TBL] [Abstract][Full Text] [Related]
46. [A differentiated approach to Parkinson's disease treatment in early stage of the disease].
Selikhova MV; Piatnitskiĭ AN; Aristova RA; Belikova LP; Vialkova AB; Gusev EI
Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(4):24-9. PubMed ID: 15270296
[TBL] [Abstract][Full Text] [Related]
47. Factors affecting levodopa effects in Parkinson's disease.
Ogawa N
Acta Med Okayama; 2000 Jun; 54(3):95-101. PubMed ID: 10925733
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone.
Trocóniz IF; Naukkarinen TH; Ruottinen HM; Rinne UK; Gordin A; Karlsson MO
Clin Pharmacol Ther; 1998 Jul; 64(1):106-16. PubMed ID: 9695725
[TBL] [Abstract][Full Text] [Related]
49. Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.
Kurth MC
Drugs Aging; 1997 May; 10(5):332-40. PubMed ID: 9143854
[TBL] [Abstract][Full Text] [Related]
50. The risk of new onset heart failure associated with dopamine agonist use in Parkinson's disease.
Mokhles MM; Trifirò G; Dieleman JP; Haag MD; van Soest EM; Verhamme KM; Mazzaglia G; Herings R; Luise Cd; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; Camp Gv; Zanettini R; Sturkenboom MC
Pharmacol Res; 2012 Mar; 65(3):358-64. PubMed ID: 22123498
[TBL] [Abstract][Full Text] [Related]
51. Levodopa and the progression of Parkinson's disease.
Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
[TBL] [Abstract][Full Text] [Related]
52. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.
Murata M; Mizusawa H; Yamanouchi H; Kanazawa I
J Neural Transm (Vienna); 1996; 103(10):1177-85. PubMed ID: 9013404
[TBL] [Abstract][Full Text] [Related]
53. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
Rascol O
Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
[TBL] [Abstract][Full Text] [Related]
54. Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
Altmann V; Schumacher-Schuh AF; Rieck M; Callegari-Jacques SM; Rieder CR; Hutz MH
Pharmacogenomics; 2016 Apr; 17(5):481-8. PubMed ID: 27019953
[TBL] [Abstract][Full Text] [Related]
55. Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease.
Nyholm D; Lennernäs H; Johansson A; Estrada M; Aquilonius SM
Clin Neuropharmacol; 2010 Jul; 33(4):181-5. PubMed ID: 20661024
[TBL] [Abstract][Full Text] [Related]
56. [Therapy for patients with progressive Parkinson's disease].
Murata M
Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1432-7. PubMed ID: 13677891
[No Abstract] [Full Text] [Related]
57. Management of neuropsychiatric symptoms in long-term care residents with Parkinson's disease: a retrospective cohort study.
Herrmann N; Marras C; Fischer HD; Wang X; Anderson GM; Rochon PA
Drugs Aging; 2013 Jan; 30(1):19-22. PubMed ID: 23188751
[TBL] [Abstract][Full Text] [Related]
58. Time until modification of antiparkinsonian therapy in a group of patients from Colombia.
Valencia-Vásquez A; Gaviria-Mendoza A; Ayala-Torres JD; Calvo-Torres F; Machado-Alba JE
Rev Neurol; 2023 Jan; 76(1):1-8. PubMed ID: 36544370
[TBL] [Abstract][Full Text] [Related]
59. [Clinical trial of the first Polish levodopa preparation in the treatment of Parkinsonian patients].
Kuran W; Kulczycki J
Neurol Neurochir Pol; 1996; 30(5):745-50. PubMed ID: 9148172
[TBL] [Abstract][Full Text] [Related]
60. Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women.
Nyholm D; Karlsson E; Lundberg M; Askmark H
Eur J Neurol; 2010 Feb; 17(2):260-6. PubMed ID: 20039939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
